Showing results (81-90 of 276) with videos related to
Sort By:
Pageof 28
Biochemical Pharmacology|March 15, 1990
Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activityN Willmott, J Cummings, E Marley, et al.Cancer Chemotherapy and Pharmacology|January 1, 1978
In vivo toxicity to lymphoid tissue by 2'-deoxycoformycinJ F Smyth, R C Young, D M YoungScience (New York, N.Y.)|October 16, 1992
Macroscopic quantum effects in nanometer-scale magnetsD D Awschalom, D P Divincenzo, J F SmythCancer Research|February 15, 1992
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell linesL R Kelland, B A Murrer, G Abel, et al.Cancer Research|November 15, 1992
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell linesP Mistry, L R Kelland, S Y Loh, et al.British Journal of Cancer|April 1, 1989
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexesC A Hills, L R Kelland, G Abel, et al.The Journal of Pharmacy and Pharmacology|January 1, 1993
The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLCJ Cummings, A MacLellan, S J Langdon, et al.Analytical Biochemistry|September 25, 2001
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cellsG Boyd, J F Smyth, D I Jodrell, et al.Biochemical Pharmacology|June 22, 1993
Correlation between tumour drug disposition and the antitumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of actionJ Cummings, N Willmott, E C Marley, et al.Anti-Cancer Drug Design|July 1, 1996
Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505J Cummings, I Meikle, J S Macpherson, et al.Pageof 28